BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 16091497)

  • 21. Medullary Thyroid Carcinoma: Prognostic Variables And Tumour Markers Affecting Survival.
    Hassan A; Siddique M; Riaz S; Khan AI; Nawaz MK; Bashir H
    J Ayub Med Coll Abbottabad; 2018; 30(Suppl 1)(4):S627-S632. PubMed ID: 30838820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma.
    Yip DT; Hassan M; Pazaitou-Panayiotou K; Ruan DT; Gawande AA; Gaz RD; Moore FD; Hodin RA; Stephen AE; Sadow PM; Daniels GH; Randolph GW; Parangi S; Lubitz CC
    Surgery; 2011 Dec; 150(6):1168-77. PubMed ID: 22136837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders.
    Elisei R; Bottici V; Luchetti F; Di Coscio G; Romei C; Grasso L; Miccoli P; Iacconi P; Basolo F; Pinchera A; Pacini F
    J Clin Endocrinol Metab; 2004 Jan; 89(1):163-8. PubMed ID: 14715844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal.
    Faggiano A; Milone F; Ramundo V; Chiofalo MG; Ventre I; Giannattasio R; Severino R; Lombardi G; Colao A; Pezzullo L
    J Clin Endocrinol Metab; 2010 Sep; 95(9):E32-6. PubMed ID: 20534767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The routine immunohistochemical diagnosis and surgical treatment of medullary carcinoma of the thyroid].
    Gavrailov M; Petkov R; Mladenov B; Todorov G; Kŭtev N
    Khirurgiia (Sofiia); 1995; 48(2):17-9. PubMed ID: 8531439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC).
    Cohen R; Campos JM; Salaün C; Heshmati HM; Kraimps JL; Proye C; Sarfati E; Henry JF; Niccoli-Sire P; Modigliani E
    J Clin Endocrinol Metab; 2000 Feb; 85(2):919-22. PubMed ID: 10690910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times.
    Laure Giraudet A; Al Ghulzan A; Aupérin A; Leboulleux S; Chehboun A; Troalen F; Dromain C; Lumbroso J; Baudin E; Schlumberger M
    Eur J Endocrinol; 2008 Feb; 158(2):239-46. PubMed ID: 18230832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin.
    Mirallié E; Iacobone M; Sebag F; Henry JF
    Eur J Surg Oncol; 2004 Sep; 30(7):790-5. PubMed ID: 15296996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma.
    Bockhorn M; Frilling A; Rewerk S; Liedke M; Dirsch O; Schmid KW; Broelsch CE
    Thyroid; 2004 Jun; 14(6):468-70. PubMed ID: 15242577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer.
    Elisei R; Lorusso L; Piaggi P; Torregrossa L; Pellegrini G; Molinaro E; Agate L; Bottici V; Pani F; Cacciato Insilla A; Casella F; Ciampi R; Tognetti I; Materazzi G; Basolo F; Romei C
    Eur J Endocrinol; 2015 Sep; 173(3):297-304. PubMed ID: 26034076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine.
    Modigliani E; Cohen R; Campos JM; Conte-Devolx B; Maes B; Boneu A; Schlumberger M; Bigorgne JC; Dumontier P; Leclerc L; Corcuff B; Guilhem I
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):265-73. PubMed ID: 9578814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
    Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
    Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination?
    Machens A; Hauptmann S; Dralle H
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2234-8. PubMed ID: 18364379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medullary thyroid carcinoma experienced at Kanazawa University Hospital.
    Mizukami Y; Nonomura A; Michigishi T; Noguchi M; Ohtake S; Nakamura S; Ishizaki T
    J Surg Oncol; 1996 Jan; 61(1):27-33. PubMed ID: 8544456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients.
    Pelizzo MR; Boschin IM; Bernante P; Toniato A; Piotto A; Pagetta C; Nibale O; Rampin L; Muzzio PC; Rubello D
    Eur J Surg Oncol; 2007 May; 33(4):493-7. PubMed ID: 17125960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma.
    Pacini F; Fontanelli M; Fugazzola L; Elisei R; Romei C; Di Coscio G; Miccoli P; Pinchera A
    J Clin Endocrinol Metab; 1994 Apr; 78(4):826-9. PubMed ID: 8157706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center.
    Kim SJ; Yun HJ; Shin SJ; Lee YS; Chang HS
    Front Endocrinol (Lausanne); 2021; 12():747704. PubMed ID: 34803914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Need for a revised staging consensus in medullary thyroid carcinoma.
    Boostrom SY; Grant CS; Thompson GB; Farley DR; Richards ML; Hoskin TL; Hay ID
    Arch Surg; 2009 Jul; 144(7):663-9. PubMed ID: 19620547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
    Salaun PY; Campion L; Bournaud C; Faivre-Chauvet A; Vuillez JP; Taieb D; Ansquer C; Rousseau C; Borson-Chazot F; Bardet S; Oudoux A; Cariou B; Mirallié E; Chang CH; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J; Kraeber-Bodéré F
    J Nucl Med; 2012 Aug; 53(8):1185-92. PubMed ID: 22743249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas.
    Weber T; Schilling T; Frank-Raue K; Colombo-Benkmann M; Hinz U; Ziegler R; Klar E
    Surgery; 2001 Dec; 130(6):1044-9. PubMed ID: 11742336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.